PanAgora Asset Management »

Black Diamond Therapeutics shares owned by PanAgora Asset Management

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by PanAgora Asset Management from 13F filings

Historical chart of PanAgora Asset Management investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by PanAgora Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by PanAgora Asset Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $546k 295k 1.85

More positions owned by PanAgora Asset Management

Nvidia Corp Common (NVDA)
Apple Common (AAPL)
Microsoft Corp Common (MSFT)
Alphabet Inc-cl A Common (GOOGL)
Amazon.com Common (AMZN)
Broadcom Common (AVGO)
Alphabet Inc-cl C Common (GOOG)
Micron Technology Common (MU)
Advanced Micro Devices Common (AMD)
Meta Platforms Inc-class A Common (META)
Eli Lilly & Co Common (LLY)
Tesla Common (TSLA)
Lam Research Corp Common (LRCX)
General Electric Common (GE)
Bank Of America Corp Common (BAC)

View all positions for PanAgora Asset Management

Top funds holding Black Diamond Therapeutics

NEA Management Company
BlackRock
Acadian Asset Management
Vanguard Capital Management
Renaissance Technologies
Defilade Capital Management
Dimensional Fund Advisors
Geode Capital Management
Connor, Clark & Lunn Investment Management
AWM Investment Company
Marshall Wace
Bridgeway Capital Management
FMR
Balyasny Asset Management
Bank of America Corporation

View all funds holding Black Diamond Therapeutics